(Press Release) Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine

January 18, 2022

Mabgenesis has entered into a joint research and development agreement with Boehringer Ingelheim of Germany for a new monoclonal antibody drug for dogs. Please see the joint press release here.